Five minutes with… James McCullough of Exosome Diagnostics
This article was originally published in Clinica
Executive Summary
James McCullough is co-founder and CEO of Exosome Diagnostics, a New York-based company that commercialises minimally-invasive molecular diagnostics using body fluids. Before taking control of the firm at its inception in 2008, he was the CEO of cardiovascular diagnostic firm AusAm Biotechnologies for more than five years
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals